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BACKGROUND: Loss-of-function mutations in hERG (encoding the Kv11.1 voltage-
gated potassium channel) cause long-QT syndrome type 2 (LQT2) because of 
prolonged cardiac repolarization. However, Kv11.1 is also present in pancreatic 
α and β cells and intestinal L and K cells, secreting glucagon, insulin, and the 
incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic 
polypeptide), respectively. These hormones are crucial for glucose regulation, 
and long-QT syndrome may cause disturbed glucose regulation. We measured 
secretion of these hormones and cardiac repolarization in response to glucose 
ingestion in LQT2 patients with functional mutations in hERG and matched healthy 
participants, testing the hypothesis that LQT2 patients have increased incretin and 
β-cell function and decreased α-cell function, and thus lower glucose levels.
METHODS: Eleven patients with LQT2 and 22 sex-, age-, and body mass index–
matched control participants underwent a 6-hour 75-g oral glucose tolerance test 
with ECG recording and blood sampling for measurements of glucose, insulin, 
C-peptide, glucagon, GLP-1, and GIP.
RESULTS: In comparison with matched control participants, LQT2 patients had 
56% to 78% increased serum insulin, serum C-peptide, plasma GLP-1, and plasma 
GIP responses (P=0.03–0.001) and decreased plasma glucose levels after glucose 
ingestion (P=0.02) with more symptoms of hypoglycemia (P=0.04). Sixty-three 
percent of LQT2 patients developed hypoglycemic plasma glucose levels (<70 
mg/dL) versus 36% control participants (P=0.16), and 18% patients developed 
serious hypoglycemia (<50 mg/dL) versus none of the controls. LQT2 patients 
had defective glucagon responses to low glucose, P=0.008. β-Cell function (Insulin 
Secretion Sensitivity Index-2) was 2-fold higher in LQT2 patients than in controls 
(4398 [95% confidence interval, 2259–8562] versus 2156 [1961–3201], P=0.03). 
Pharmacological Kv11.1 blockade (dofetilide) in rats had similar effect, and small 
interfering RNA inhibition of hERG in β and L cells increased insulin and GLP-1 
secretion up to 50%. Glucose ingestion caused cardiac repolarization disturbances 
with increased QTc intervals in both patients and controls, but with a 122% greater 
increase in QTcF interval in LQT2 patients (P=0.004).
CONCLUSIONS: Besides a prolonged cardiac repolarization phase, LQT2 
patients display increased GLP-1, GIP, and insulin secretion and defective 
glucagon secretion, causing decreased plasma glucose and thus increased 
risk of hypoglycemia. Furthermore, glucose ingestion increased QT interval and 
aggravated the cardiac repolarization disturbances in LQT2 patients.
CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: 
NCT02775513.
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Voltage-gated potassium (Kv) channels are known for their relation to malignant cardiac arrhythmias, where blocked or nonfunctional Kv channels cause 
long-QT syndrome (LQTS) because of impaired cardiac 
repolarization. Several inheritable mutations and many 
common drugs impair the function of Kv channels.
1–5 
LQTS attributable to inherited mutations affects up to 
1:2000 people. It is characterized by a prolonged QT 
interval and increases the risk of ventricular tachycardia 
of the Torsades de Pointes type, syncope, and sudden 
death.3,4 Mutations in KCNQ1 cause LQTS type 1 (LQT1) 
attributable to impaired Kv7.1 channel function. Muta-
tions in hERG (also known as KCNH2), cause LQTS type 
2 (LQT2) because of impaired function of the pore-form-
ing α-subunit of the voltage-gated Kv11.1 channel, which 
is a key player of repolarization in cardiac cells.3 LQT2 
is the second most common type of congenital LQTS, 
and is specifically characterized by notched T waves in 
the ECG4 and a tendency to develop arrhythmias during 
sudden startling.5
Voltage-gated potassium (Kv) channels also play a role 
in glucagon and insulin secretion from the pancreatic 
α and β cells1,6–9 and possibly also in the secretion of 
the incretin gut hormones, glucagon-like peptide (GLP-
1) and glucose-dependent insulinotropic peptide (GIP), 
secreted from intestinal L and K cells, respectively.10 
These hormones are crucial for glucose regulation, and 
LQT1 patients have hyperinsulinemia and postprandial 
hypoglycemia.7 Blockade of Kv11.1 channels results in 
depolarization of the resting membrane potential and in-
creases action potential firing rate by 32% (investigated 
by patch-clamp technique) and the release of insulin by 
77% in human pancreatic β cells.9 Blocking Kv11.1 chan-
nels in α cells impairs glucagon secretion.8 Both condi-
tions decrease glucose levels. Hypoglycemia is associ-
ated with increased propensity for QT prolongation and 
other adverse cardiovascular effects.11–13
Therefore, we investigated whether LQT2 patients 
with functional mutations in hERG and impaired Kv11.1 
channel function have increased glucose-stimulated in-
sulin and incretin secretion and decreased levels of glu-
cagon resulting in decreased glucose levels after oral 
glucose ingestion.
METHODS
Study Participants
Eleven LQT2 patients with loss-of-function mutations in hERG 
were recruited from the outpatient clinic at the Cardiology 
Department at Gentofte Hospital, Denmark. Two control sub-
jects, matched to each individual patient with respect to body 
mass index (BMI), age, and sex, were recruited for examina-
tion in the present study from regional population-based stud-
ies, the Inter99, Health2006,2010, or DanFund studies.14,15 A 
computer algorithm, developed by a data manager indepen-
dent of the research study, was applied to randomly select 
the control subjects based on their match with respect to sex, 
±1 BMI, and age (±3 years), inviting the closest matches first 
for participation in the study. Updated BMI and age were used 
for matching. Control participants were excluded if they were 
diagnosed with any known chronic disease, including diabetes 
mellitus, but were not screened for prediabetes because this 
could induce selection bias toward a falsely healthier metabolic 
phenotype given their BMI.
Before examination, all participants were fasting overnight 
and were free of any medication in the morning before exami-
nation. Ten of 11 LQT2 patients were on β-blocking agents, 
7 had an implantable cardioverter-defibrillator, and 1 had a 
pacemaker.
Ethics
Before participation, informed written consent was obtained 
from all participants. The project was approved by The 
Clinical Perspective
What Is New?
• Patients with long-QT syndrome type 2 (LQT2) with 
loss-of-function mutations in hERG (Kv11.1) display 
exaggerated incretin and endocrine pancreatic func-
tion with >50% increased levels of circulating insu-
lin, glucagon-like peptide-1and glucose-dependent 
insulinotropic polypeptide, and defective glucagon 
secretion, causing low plasma glucose levels, and 
thus increased risk of symptomatic reactive hypo-
glycemia following glucose ingestion.
• Pharmacological Kv11.1 blockade (dofetilide) in rats 
had similar effects and inhibition of hERG in β and 
L cells increased insulin and glucagon-like peptide-1 
secretion with up to 50%.
• Furthermore, glucose ingestion aggravated cardiac 
repolarization disturbances in LQT2 patients with 
a 122% greater increase in QTcF interval and pro-
longed the cardiac repolarization phase in healthy 
controls.
What Are the Clinical Implications?
• Glucose ingestion (75 g, equivalent of 0.6 L soft 
drink) led to symptomatic reactive hypoglycemia in 
63% of LQT2 patients with 18% experiencing seri-
ous hypoglycemia (<50 mg/dL glucose).
• Serious hypoglycemia has previously been observed 
in children with LQT2, long-QT syndrome type 1, and 
with Kv11.1 blocking drugs.
• Hypoglycemia leads to increased propensity for QT 
prolongation; hypoglycemia may therefore further 
increase the risk of malignant arrhythmia in patients 
with long-QT syndrome.
• Our demonstration of LQT2 patients having 
increased risk of hypoglycemia should lead to a 
greater awareness of this risk.
• The risk of hypoglycemia can be lessened by reduc-
ing intake of easily digestible carbohydrates.
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Committees on Health Research Ethics in the Capital Region 
of Denmark (reference number: H-4-2010-036) (institutional 
review board) and was performed in accordance to the 
Helsinki Declaration II. The participants gave informed con-
sent, participation in the investigation was voluntary, and the 
individuals could retract their consent to participate at any time 
(ClinicalTrials.gov Identifier: NCT02775513).
Study approval for the animal study was obtained from 
the Danish Animal Experiments Inspectorate (2013-15-2934-
00833) and the procedures followed were in accordance with 
institutional guidelines.
Genetics
All patients were originally screened for functional mutations 
known to cause LQTS.16 The LQT2 patients were all hetero-
zygous carriers from 5 different families with the following 
functional missense mutations: hERG K101E (4 patients, 
grandmother, mother, son, and daughter), hERG I96T (1 
patient), hERG F29L (2 patients, mother and son), hERG 
I400N (2 patients, mother and daughter), or hERG G572R (2 
patients, aunt and niece).17,18 The first 3 mutations mentioned 
are located in the Per-Arnt-Sim (PAS) domain, which contains a 
signal-sensing region and causes trafficking defects.19 I400N 
is in the S1 transmembrane segment and disrupts the voltage-
sensing unit.17 G572R is in the S5 transmembrane segment 
and the pore-forming unit, and causes reduced activation of the 
channel or disturbs the channel’s gating properties.18
Oral Glucose Tolerance Test
Blood samples for measurements of plasma glucose, serum 
insulin, serum C-peptide, plasma total GLP-1, plasma total 
GIP, plasma glucagon, and serum potassium were taken after 
an overnight fast and during a 6-hour 75-g oral glucose toler-
ance test (OGTT). Fasting blood samples were taken 15, 10, 
and 0 minutes before glucose ingestion. Blood sampling was 
repeated every 15 minutes for the first hour and every half 
hour for the following 5 hours.
Blood Samples
Plasma glucose was measured by a colorimetric assay on 
an automated Vitros 5.1 FS/5600 analyzer (Ortho Clinical 
Diagnostics) with a lower limit of quantitation of 19.8 mg/dL 
and intra- and interassay coefficients of variation of 0.025.
Hypoglycemic glucose values were defined as blood glu-
cose <70 mg/dL. The generic nondiabetic glycemic thresh-
old for impairment of cognitive function is <50 mg/dL20. This 
level was defined as serious hypoglycemia based on The 
International Hypoglycemia Group guidelines.20
Serum potassium was measured using Vitros 5.1 FS/5600 
analyzer (Ortho Clinical Diagnostics). Intra- and interassay coef-
ficients of variation were 0.05. The analytic detection limit was 
1 mmol/L.
Serum insulin and C-peptide were both measured on an 
automated Cobas e411 analyzer (Roche). The analytic detec-
tion limit was 1.4 and 3 pmol/L with total intra- and interassay 
coefficients of variation of <0.04 and <0.025, respectively.
Plasma levels of total GLP-1, total GIP, and glucagon were 
measured with validated radioimmunoassays.21–23 The assays 
have a detection limit of <2 pmol/L (1 pmol/L for glucagon) 
and intra-assay and interassay coefficients of variation of 
<0.06 and 0.15, respectively.
Electrocardiography
ECG recordings (MAC1600 ECG machine [GE Healthcare]) were 
made before each blood sampling: 5 minutes before glucose 
ingestion and repeated every 15 minutes for the first hour after 
glucose ingestion and then every half-hour for the following 5 
hours. The mean of 5 consecutive recordings at each time 
point was used. QT intervals were corrected by heart rate with 
the Bazett formula (QTcB= QT/(RR)1/2), and the Fridericia for-
mula (QTcF = QT/(RR)1/3).
Hypoglycemia Questionnaire
An electronic questionnaire in the software SurveyXact was 
completed by all participants before examination. The ques-
tionnaire included an adapted standard questionnaire for symp-
toms of hypoglycemia.7
Continuous Glucose Monitoring
Continuous blood glucose monitoring (CGM) was performed 
after the baseline examination using iPro2 (Medtronic) for a 
duration of between 3 and 7 days according to clinical recom-
mendations24 and following the manufacturer’s manual. Only 
6 of 11 LQT1 patients agreed to be investigated by CGM and 
were matched with 6 control participants. Results are shown 
in the online-only Data Supplement Appendix (online only Data 
Supplement Table I).
Biochemical and Anthropometric Measures
Height and weight of LQT2 patients and control participants 
(without shoes and wearing light indoor clothes) were mea-
sured before examination; BMI was calculated as weight in kilo-
grams divided by the square of height in meters (kg/m2). The 
percentage of fat was measured with a bioimpedance analyzer, 
Biodynamics BIA 310e (Biodynamics).
OGTT in Rats
Twenty-two female Wistar rats were assigned to 2 weight-
matched groups and received an intravenous injection under 
isoflurane anesthesia of dofetilide (5 mg/kg) or vehicle 15 
minutes before glucose gavage feeding (2 g/kg) (time, 0 
minutes). Further details are described in the online-only Data 
Supplement Appendix.
Cell Studies
siRNAs against hERG were obtained and acute stimulation 
with and without glucose (180 mg/dL) of cultured L (GLUTag) 
and β (Min-6) cells (with/without siRNA hERG), using ≈80% 
confluent cells from different batch numbers (n=3), were per-
formed. Further details are described in the online-only Data 
Supplement Appendix.
Calculations
Total AUC was calculated as the total area under the curve with 
y=0 as baseline. Incremental and decremental AUC, defined as 
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the AUC above or below fasting level (mean of time point −15, 
−10, and 0), respectively, were calculated in GraphPad Prism 
5 (GraphPad Software Inc) using the trapezoidal method with 
the fasting levels as baseline for the time curve.
Responses were divided into 3 time intervals: the acute 
response (0–30 minutes), the standard 2-hour response (0–
120 minutes), and the extended full 6-hour response (0–360 
minutes) to 75-g glucose ingestion.
Insulinogenic index [(serum insulin at 30 minutes – fast-
ing serum insulin) / (plasma glucose at 30 minutes – fasting 
plasma glucose)] was calculated as a measure of β-cell function 
and describes early phase insulin secretion. Whole-body insulin 
sensitivity was estimated from oral glucose tolerance data by 
applying the Matsuda insulin sensitivity index: (10 000/√(fast-
ing plasma glucose × fasting serum insulin × mean plasma 
glucose for the first 2 hours × mean serum insulin for the 
first 2 hours). Insulin resistance was estimated with the fast-
ing homeostasis model assessment of insulin resistance index 
(HOMA-IR) and calculated as follows: (fasting plasma glucose 
× fasting serum insulin)/405. Disposition index was calculated 
as insulinogenic index divided by HOMA-IR. β-Cell function 
corrected for insulin sensitivity was assessed by the Insulin 
Secretion Sensitivity Index-2 (ISSI-2). ISSI-2 is a validated OGTT-
derived measure of β-cell function similar to the disposition 
index. ISSI-2 has been validated against the disposition index, 
calculated on the basis of a frequently sampled intravenous 
glucose tolerance test, with which it exhibits a stronger cor-
relation than other OGTT-derived measures of β-cell function. 
ISSI-2 is defined as the product of insulin secretion as mea-
sured by the ratio of incrementalAUCinsulin0-120 to incrementalAUCglucose0-120 
and insulin sensitivity as measured by the Matsuda index: 
Matsuda Index × (incrementalAUCIns0–120 / incrementalAUCGluc0-120).
25,26
The frequency and severity of hypoglycemia symptoms 
were quantified by analyzing the adapted hypoglycemia ques-
tionnaire.7 The total frequency and severity score was calcu-
lated for each participant as the sum of points for all frequency 
and severity questions.
The acute cardiac responses to glucose ingestion evalu-
ated as QTcB and QTcF in the recorded ECGs were found 
by analyzing the maximum ∆ increase within the first 30 
minutes of the OGTT and subtracting the fasting value to 
analyze response differences between patients and healthy 
controls.
Sample Size Calculation
Our prior data on LQT1 patients7 indicated that a difference 
of 2000 pmol/L×min in the incrementalAUC(0–30) insulin response 
between 11 matched pairs would reject the null hypothesis 
that this response difference is zero with power 0.8, P<0.05. 
With our present data on 11 patients and 22 matched controls 
and a difference of 2471 pmol/L×min±489, we have a power 
>0.9, P<0.05 (paired design).
Statistics
Prespecified primary variables were area under the curve 
(AUC) for hormones and glucose.
Statistical analyses were made in SAS Enterprise Guide 
7.11, SAS institute. Data distribution was studied before further 
analyses and insulin data were consequently log-transformed.
Mixed-model analysis of variance (ANOVA) with family muta-
tion as an additional factor was performed on patient group 
data. There were no significant differences between the 5 fami-
lies. Consequently, data were analyzed by using mixed-model 
ANOVA contrasting LQT2 patients versus control participants 
in matching pairs.
The Fisher exact test was used to analyze the difference in 
occurrence of hypoglycemic plasma glucose values between 
patients and matched control participants during the OGTT.
Differences in fasting, decrementalAUC0-120min and incrementalAUC120-360min 
glucagon responses of hypoglycemic versus nonhypoglycemic 
patients, were analyzed with unpaired t tests.
Questionnaire data were quantified as numeric categorical 
data, and differences in mean scores between patients and 
control participants were tested with a paired t test.
Changes in QTcB, QTcF, and heart rate from baseline during 
the OGTT were analyzed with a proc mixed ANOVA to study 
cardiac repolarization disturbances after glucose stimulation, 
and, if interaction between time and group was identified, the 
groups were subsequently analyzed separately.
Data are presented as mean±standard error of the mean 
or geometric mean (95% confidence interval) for log-trans-
formed data. A P value of <0.05 was considered statistically 
significant.
RESULTS
Baseline Characteristics
The patients with LQT2 and the healthy control partici-
pants were successfully matched with regard to sex, 
age, BMI, and fat percentage and heart rate, as well 
(Table 1). LQT2 patients had longer QTcB and QTcF inter-
vals than control participants (Table 1).
Fasting Circulating Hormone Levels
Patients with LQT2 had 32% lower fasting plasma lev-
els of glucagon in comparison with control participants 
Table 1. Subject Characteristics
Characteristics
Long-QT 
Syndrome  
Type 2 Patients
Control 
Participants Ppatient vs control
Total no. (men/
women)
11 (2/9) 22 (4/18)  
Age, y 42±6 42±4 1.0
Body mass index, 
kg/m2
23.4±0.8 24.0±0.7 0.6
Fat, % 26.5±1.8 26.8±1.9 0.9
Fasting QTcB, ms 477±7 419±6 <0.0001
Fasting QTcF, ms 485±8 423±7 <0.0001
Fasting heart rate, 
beats/min
55.0±2.8 57.8±1.2 0.4
Subject characteristics were analyzed with a mixed-model analysis of 
variance. Data are shown as mean±standard error of the mean.
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(4.1±0.8 versus 6.0±0.7 pmol/L, P=0.02). There were 
no differences between LQT2 patients and control par-
ticipants in fasting levels of plasma glucose, serum in-
sulin, serum C-peptide, plasma GLP-1, plasma GIP, or 
serum potassium (Figures 1 and 2).
There were no differences in fasting hemoglobin A1c 
(33.8±1.2 [range, 28–38] versus 34.8±1.0 [range, 
29–44 mmol/mol]) P=0.4, fasting hemoglobin (8.2±0.1 
versus 8.4±0.1 mmol/L) P=0.1, fasting total cholesterol 
(4.8±0.4 versus 4.7±0.3 mmol/L) P=0.7, or fasting cre-
atinine (64.6±3.1 versus 64.7±2.2 µmol/L) P=1.0 be-
tween groups. None of the participants had hemoglobin 
A1c levels ≥48 mmol/mol (definition of diabetes mellitus).
Glucose-Stimulated Hormone Responses
LQT2 patients had lower glucose levels during the 6-hour 
OGTT than control participants (mean glucose during 
the 6 hours was 97±4 mg/dL versus 106±2 mg/dL, 
P=0.02 with a 16% smaller 2-hour total AUC, P=0.03, 
and 6-hour total AUC, P=0.02 (Table 2, Figure 1A). A 
higher proportion of patients with LQT2 developed hy-
poglycemia (plasma glucose levels <70 mg/dL) during 
the OGTT than control participants (7/11=63% versus 
8/22=36%, respectively), although the difference was 
not significant given the sample size (P=0.16 by Fisher 
exact test). During the 6-hour OGTT with 17 measure-
ments, the 11 patients had 16 hypoglycemic measure-
ments in comparison with 13 hypoglycemic measure-
ments in the 22 matched control participants. Two 
patients with LQT2, but no healthy participants, devel-
oped serious hypoglycemia (plasma glucose <50 mg/
dL) at 3 time points during the OGTT (lowest registered 
plasma glucose was 43 mg/dL after 150 minutes and 
45 mg/dL after 180 minutes, respectively), P=0.04. Six 
of 7 hypoglycemic LQT2 patients had mutations (F29L, 
K101E, and 196T) in the PAS domain (including the 2 
with serious hypoglycemia [I96T and K101E]) in contrast 
to the 4 nonhypoglycemic LQT2 patients where 3 of 4 
had mutations in the transmembrane segment S1 or S5.
A B
C D
Figure 1. Plasma glucose and hormone responses to oral glucose ingestion in 11 LQT2 patients and 22 matched 
healthy control participants.  
Glucose (A), insulin (B), glucagon (C), and C-peptide (D) fluctuations during a 6-hour oral 75-g glucose tolerance test, shown as 
mean±SEM for non–log-transformed data. LQT2 patients, red full lines; control participants, blue broken lines. LQT2 indicates 
long-QT syndrome type 2; and SEM, standard error of the mean.
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LQT2 patients had increased serum insulin and C-pep-
tide responses to oral glucose. Thus, 30-minute insulin 
and C-peptide responses (incrementalAUC(0–30)) were 57% and 
60% higher in patients with LQT2 than in matched control 
participants (P=0.03 and 0.004), along with increased 
C-peptide after 2 hours (incremental AUC(0–120), P=0.03) (Ta-
ble 2, Figure 1B and 1D).
LQT2 patients had also increased incretin responses 
to oral glucose. Thus, GLP-1 responses were 56% to 
94% higher in patients than in controls at 30 minutes, 
2 hours, and 6 hours (incrementalAUC, P=0.01–0.003). 
The 2-hour response of GIP was increased by 78% in 
comparison with controls (P=0.02) (Table 2, Figure 2A 
and 2B).
There was no difference in potassium responses to 
glucose between the groups, P>0.1 (Figure 2C).
During the OGTT, the LQTS patients had lower glucagon 
response to low glucose on oral glucose stimulation (decre-
mentalAUC0-360), P=0.008, Table 2) than controls (Figure 1C). 
Furthermore, the 7 of 11 LQT2 patients that developed 
hypoglycemic plasma glucose levels <70 mg/dL during 
the OGTT had lower glucagon response to low glucose 
levels during the OGTT than the 4 patients that did not de-
velop hypoglycemia (incremental AUC(120–360) 285±59 versus 
648±28, P=0.004). Fasting and decrementalAUC(0–120) gluca-
gon was 3.6±2.6 versus 4.9±1.7, P=0.07, and 134±89 
versus 269±54, P=0.1, respectively Figure 3.
β-Cell function measured by insulinogenic index 
was 167% increased in LQT2 patients in compari-
son with control participants (P=0.001, Figure 4A). 
There was no difference between patients and con-
trol participants regarding insulin sensitivity measured 
by the Matsuda index (geometric mean values [95% 
confidence interval], 16.0 [12.6–20.3] versus 18.3 
[14.1–23.7], P=0.5) or insulin resistance measured 
by HOMA-IR (1.3 [1.0–1.6] versus 1.2 [0.9–1.7] (mg/
dL)×(mIU/mL), P=0.9). The insulin sensitivity–ad-
justed β-cell function in LQT2 patients, measured by 
ISSI-2, was 2-fold higher than in control participants 
with geometric mean values [95% confidence interval] 
for patients with LQT2 of 4398 [2259–8562] versus 
control participants 2156 [1961–3201], P=0.03 (Fig-
ure 4B). β-Cell function measured by the disposition 
index was 233% higher in hERG patients (23.5 [11.8–
46.8] versus 10.1 [5.3–17.0] in control participants, 
P=0.002).
Glucose-Stimulated ECG Responses
The duration of QTcB and QTcF was longer in LQT2 pa-
tients than in control participants during the 6-hour OGTT 
(Figure 5), P<0.0001.
Glucose ingestion led to a biphasic QTc and heart rate 
response. QTc increased in both groups after 15 to 45 
minutes, and was increased again 300 minutes after glu-
cose ingestion, P<0.05 to 0.0001 (Figure 5). The maxi-
mum acute increase of QTc (0–30 minutes) was 77(for QTcB)% 
to 122(for QTcF)% larger in patients with LQT2, in comparison 
with control participants, P=0.01 to 0.004, whereas the 
A
B
C
Figure 2. Incretin and potassium responses to 
oral glucose ingestion in 11 LQT2 patients and 22 
matched healthy control participants.  
GLP-1 (A), GIP (2), and potassium (C) fluctuations during 
a 6-hour oral 75-g glucose tolerance test, presented as 
mean±SEM. LQT2 patients, red full lines; control participants, 
blue broken lines. GIP indicates glucose-dependent insulinotro-
pic polypeptide; GLP-1, glucagon-like peptide-1; LQT2, long-
QT syndrome type 2; and SEM, standard error of the mean.
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Table 2. Hormone and Glucose Responses During Oral Glucose Tolerance Test
 
Long-QT Syndrome  
Type 2 Patients
Control  
Participants P Value
Total area under the curve
  0–120 min    
   C-peptide (pmol/L×min) 275 973±22 554 233 846±17 455 0.1
   GIP (pmol/L×min) 5195±463 4376±376 0.1
   GLP-1 (pmol/L×min) 2774±250 2617±187 0.6
   Glucagon (pmol/L×min) 323±53 388±41 0.3
   Glucose (mg/dL×min) 13 242±865 15 710±613 0.03*
   Insulin (pmol/L×min) 40 107±4947 32 694±3498 0.2
  0–360 min    
   C-peptide (pmol/L×min) 509 764±47 780 472 385±40 052 0.4
   GIP (pmol/L×min) 9320±772 8004±607 0.1
   GLP-1 (pmol/L×min in) 6354±458 6206±326 0.9
   Glucagon (pmol/L×min) 1258±177 1460±142 0.3
   Glucose (mg/dL×min) 33 113±1261 36 590±937 0.02*
   Insulin (pmol/L×min) 56 954±7863 52 260±5600 0.6
Incremental and decremental area under the curve
  0–30 min    
   C-peptide (pmol/L×min) 26 613±2546 16 645±1800 0.004*
   GIP (pmol/L×min) 845±86 650±61 0.07
   GLP-1 (pmol/L×min) 383±57 197±40 0.01*
   Glucagon (pmol/L×min) –21.2±7.9 –38.2±7.2 0.02*
   Glucose (mg/dL×min) 712±85 778±106 0.6
   Insulin (pmol/L×min) 6786±843 4315±596 0.03*
  0–120 min    
   C-peptide (pmol/L×min) 210 371±17 888 160 148±13 085 0.03*
   GIP (pmol/L×min) 4437±394 3451±328 0.02*
   GLP-1 (pmol/L×min) 1521±199 851±161 0.003*
   Glucagon (pmol/L×min) –183±62 –340±55 0.01*
   Glucose (mg/dL×min) 3027±829 4630±595 0.1
   Insulin (pmol/L×min) 35 707±4263 27 182±3015 0.1
  0–360 min    
   C-peptide (pmol/L×min) 304 073±30 777 264 009±25 202 0.2
   GIP (pmol/L×min) 6567±729 5418±576 0.2
   GLP-1 (pmol/L×min) 2284±324 1334±258 0.01*
   Glucagon (pmol/L×min) -334±160 -761±142 0.008*
   Glucose (mg/dL×min) 3549±1009 5729±721 0.09
   Insulin (pmol/L×min) 44 250±6175 38 658±4466 0.5
Two-hour and 6-h total area under the curve and incremental and decremental acute (0–30 min), 2 h 
(0–120 min), and full (0–360 min) area under the curve hormone response during OGTT in 11 LQT2 patients 
and 22 matched control participants analyzed with a mixed-model analysis of variance. Data are shown as 
mean±standard error of the mean. GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like 
peptide-1; LQT2, long-QT syndrome type 2; and OGTT, oral glucose tolerance test.
*P<0.05.
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heart rate increase was similar between groups (Figure 5 
and online-only Data Supplement Table II).
Questionnaire
LQT2 patients reported more symptoms of hypoglyce-
mia (23.8±2.2 versus 19.3±1.5 points, P=0.04; Fig-
ure 6) and experienced more severe symptoms, if a 
meal was missed, and more often reported feeling un-
comfortable a couple of hours after a meal (online-only 
Data Supplement Table III). Furthermore, patients with 
LQT2 experienced more frequent and severe symptoms 
if they suddenly stood up from a sitting position, and 
reported increased frequency of heart palpitations, and 
occasional fainting, as well.
Pharmacological Blockage of Kv11.1 During 
OGTT in Rats
Rats receiving the selective Kv11.1 channel blocker 
dofetilide (antiarrhythmic drug)27,28 had increased insulin 
secretion, and corresponding reduced blood glucose lev-
els after glucose intake in comparison with rats receiving 
vehicle, P<0.01 (Figure 4C and 4D). Sixty-three percent 
of rats receiving dofetilide developed glucose values 
lower than their fasting levels during the 1-hour OGTT in 
comparison with 25% of rats in the vehicle group.
hERG Blockage in Cultured L and β-Cells
Glucose-induced GLP-1 secretion was significantly 
higher (24%, P=0.009) in cultured L cells with knock-
down of hERG expression (siRNAhERG) in comparison 
with control cells (siRNAmock). Glucose-induced insulin 
secretion was significantly higher (54%, P=0.001) in 
cultured β cells with knockdown of hERG expression 
(siRNAhERG) in comparison with control cells (siRNAmock) 
(Figure 4E and 4F).
DISCUSSION
Here, we show that besides a prolonged cardiac repo-
larization phase, patients with LQT2 caused by hERG 
mutations display exaggerated incretin and endocrine 
pancreatic function with >50% increases in GLP-1, GIP, 
and insulin secretion, and defective glucagon secre-
tion, causing low plasma glucose levels and increased 
risk of symptomatic hypoglycemia following glucose in-
gestion. Pharmacological Kv11.1 blockade (dofetilide) 
in rats had similar effects and inhibition of hERG in β 
and L cells directly increased insulin and GLP-1 secre-
tion up to 50%. Furthermore, glucose ingestion aggra-
vated cardiac repolarization disturbances in LQT2 pa-
tients and prolonged the cardiac repolarization phase 
in healthy controls.
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Figure 3. Plasma glucagon 
response to oral glucose among 
LQT2 patients with (n=7) and 
without (n=4) hypoglycemia.  
The 7 of 11 LQT2 patients that devel-
oped hypoglycemic plasma glucose 
levels <70 mg/dL during the OGTT 
had lower glucagon response to low 
glucose levels during the OGTT than 
the 4 patients that did not develop 
hypoglycemia (incremental AUC120-360 
285±59 versus 648±28, P=0.004) 
analyzed with an independent t test. 
LQT2 patients with hypoglycemia, 
full lines; LQT2 patients without 
hypoglycemia, broken lines. Data are 
shown as mean±SEM. AUC indicates 
area under the curve; LQT2, long-QT 
syndrome type 2; OGTT, oral glucose 
tolerance test; and SEM, standard 
error of the mean.
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Figure 4. Inhibition of hERG in humans, rats, and cells. 
Differences in β-cell function in response to oral glucose ingestion in 11 LQT2 patients and 22 matched healthy control partici-
pants. β-Cell function measured by insulinogenic index (A) and Insulin Secretion-Sensitivity Index-2 (ISSI-2), which is a validated 
OGTT-derived measure of insulin sensitivity–adjusted β-cell function (B) analyzed with a mixed-model ANOVA. Insulinogenic index 
and ISSI-2 are shown as geometric means [95% CI]. C and D, Oral glucose tolerance test in rats. Rats receiving the selective 
Kv11.1 channel blocker dofetilide (antiarrhythmic drug) (n=8) had increased insulin secretion and reduced blood glucose (incremental 
AUC0-60 439±182 versus 1218±175) after glucose intake in comparison with rats receiving vehicle (n=14), P<0.01. (Continued ) 
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Functional Role of Kv11.1 Channels in Human 
Glucose Regulation
Until now, the functional role of Kv11.1 channels in hu-
man glucose regulation has been unknown, although 
several endocrine cell studies have shown that Kv11.1 
is expressed in α (glucagon), β (insulin),1,6,8,9 L (GLP-1),10 
and likely K cells (GIP) (identified by microarray, personal 
communication, Fiona Gribble, Cambridge University, UK, 
2016) in the pancreas and intestines, respectively. Our re-
sults show that reduced function of Kv11.1 is associated 
with acute hyperinsulinemia, >50% increased GLP-1 and 
GIP levels, and correspondingly lower plasma glucose lev-
els after a standard oral 75-g glucose load. The LQT2 pa-
tients had 2-fold higher β-cell function, ie, the ability to se-
crete more insulin on glucose ingestion, also when taking 
the insulin sensitivity status into account. We also show 
that inhibition of hERG directly increases secretion of both 
insulin and GLP-1 from cultured β and L cells, respectively. 
These results combined with previously published electro-
physiology studies of hERG blockade in human β cells8,9 
support that blocking Kv11.1 has a direct effect on both 
insulin- and GLP-1–producing cells. Thus, although a 
nonincretin-dependent test of β-cell function (eg, an intra-
venous glucose tolerance test) was not performed, the 
hyperinsulinemia in hERG mutation carriers seems to be 
attributable to a dual effect: a direct stimulatory effect on 
β cells causing increased insulin secretion, and an indirect 
effect attributable to increased secretion of GLP-1 (and 
GIP) from L (– and K) cells, which in turn also stimulates 
insulin secretion and thereby lowers blood glucose.
The glucagon levels were lower in LQT2 patients than 
in matched control participants, even though they had 
lower glucose levels, which is an indication of distorted α-
cell function, because, under normal physiological circum-
stances, hypoglycemia would be expected to increase 
glucagon levels to counteract the hypoglycemia. Indeed, 
the hypoglycemic LQT2 patients had an inappropriately 
low increase in glucagon during low glucose levels in 
comparison with the nonhypoglycemic LQT2 patients. 
Furthermore, inhibition of Kv11.1 channels in α cells leads 
to an inhibition of glucagon secretion.8 Exocytosis in α 
cells is caused by membrane potential–dependent open-
ing of the Cav channels mediating the calcium entry. With 
inhibition of the Kv current, there is no reactivation of the 
Nav channels and Cav channels leading to a marked reduc-
tion of the action potential amplitude, thereby inhibiting 
glucagon release. As a consequence, glucagon secretion 
is decreased when Kv channels are blocked
8,29,30 or dys-
functional as in LQT2 patients. Therefore, LQT2 patients 
have impaired counterregulatory defense against hypogly-
cemia. Glucagon was measured with a method recently 
validated versus mass spectrometry and has a detection 
limit of 1 pmol/L. We therefore consider the measured 
plasma levels of glucagon to be accurate.31
Clinical Implications of Higher Risk of 
Hypoglycemia
During the 6-hour OGTT, 63% of LQT2 patients became 
hypoglycemic, including 18% with serious hypoglycemia 
(<50 mg/dL glucose) versus 36% control participants 
among whom none became seriously hypoglycemic. 
Patients with LQT2 reported more symptoms of hypo-
glycemia in daily life, such as discomfort if a meal was 
missed, and discomfort some hours after meal intake, 
as well, in comparison with control participants. Some 
symptoms of hypoglycemia, like palpitations, are over-
lapping with symptoms of LQTS.
Hypoglycemia is associated with increased propen-
sity for QT prolongation and other adverse cardiovascu-
lar effects.11–13 Furthermore, a high-baseline QTc interval 
seems to be an important predictor for hypoglycemia-
induced QTc prolongation.32 The combination of symp-
tomatic reactive hypoglycemia with LQT2 may therefore 
further increase the propensity for cardiac events in pa-
tients with LQT2. In line with these observations, children 
with LQT2 were found to have higher risk of developing 
severe hypoglycemia in a large retrospective study that 
called for awareness of this.33 Because the study was 
retrospective, analyzing historical hospital data,33 oral 
glucose tolerance tests were not performed. Thus, it is 
unknown whether the children also experienced reactive 
hypoglycemia.
Our findings further suggest that, similar to functional 
KCNQ1 mutations,7 functional hERG mutations may un-
derlie some cases of essential postprandial hypoglyce-
mia. This syndrome is characterized by appearance of 
reactive hypoglycemia after food intake without conspic-
uous cause. Thus, ECG monitoring and genetic testing 
could be considered when other causes of reactive hy-
poglycemia (eg, gastrointestinal surgery or medications) 
have been excluded.
An additional important finding in our study is that 
an increase of plasma glucose by only 54 to 72 mg/
Figure 4 Continued. Analyzed by an independent t test. E and F, Cultured β- and L-cell insulin and GLP-1 responses to glu-
cose on hERG inhibition with siRNA. Glucose-induced GLP-1 secretion was significantly higher (24%, P=0.009) in cultured L cells 
with knockdown of hERG expression (siRNAhERG) in comparison with control (siRNAmock) (siRNA knockdown efficiency=70±12%). 
Glucose-induced insulin secretion was significantly higher (54%, P=0.001) in cultured β cells with knockdown of hERG expression 
(siRNAhERG) in comparison with control (siRNAmock) (siRNA knockdown efficiency=75±8%). Analyzed with 1-way ANOVA with Sidak 
correction. Data are shown as mean±SEM. *P<0.05. **P<0.01. ***P<0.001. ****P<0.0001. ANOVA indicates analysis of vari-
ance; AUC, area under the curve; CI, confidence interval; GLP-1, glucagon-like peptide-1; LQT2, long-QT syndrome type 2; OGTT, 
oral glucose tolerance test; PBS, phosphate –buffered saline; SEM, standard error of the mean; and siRNA, small interfering RNA. 
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dL during the OGTT affected heart rate and cardiac re-
polarization in both LQT2 patients and healthy control 
participants. However, the disturbances were more pro-
nounced in patients with LQT2. Because LQT2 patients 
have a prolonged QT interval, they are more vulnerable 
to further increases in their QT interval than healthy in-
dividuals.34 Interestingly, patients with both type 1 and 
type 2 diabetes mellitus experience prolonged QT inter-
val because of a downregulation of Kv11.1 channels
35,36 
and because plasma glucose levels influence the normal 
Kv11.1 channel function via ATP.
9–11 During hyperglyce-
mia, increased cell metabolism will increase ATP produc-
tion and thereby close the KATP channels. In cardiomyo-
cytes, this may prolong the repolarization phase and thus 
increase QT interval, also in healthy individuals. Howev-
er, patients with LQT2 seem to be even more vulnerable 
to cardiac events in response to glycemic excursions, 
which, by disturbing repolarization further, increase the 
risk of QT dispersion and possible malignant arrhyth-
mias. During the prolonged OGTT, a biphasic QTc curve 
was observed, high during peak glucose, lowest at 180 
minutes, but then rising again. The lowest glucose levels 
were observed at 200 minutes, but thereafter remained 
low. Thus, the net result of glucose ingestion seems to 
be QT prolongation both during hyperglycemia, but also 
during the prolonged, relatively hypoglycemic state 5 
hours after glucose ingestion.
There were no differences in fasting hemoglobin A1c 
or CGM between groups (CGM was only performed in half 
of the patients and not in any of the seriously hypoglyce-
mic patients). This likely reflects that the fasting glucose 
levels were similar between the groups and that only a 
small fraction of the day is spent in a postprandial state 
where the differences between groups were pronounced. 
Furthermore, because patients with LQT2 reported more 
symptoms of hypoglycemia in daily life (discomfort if a 
Figure 5. QTc and heart rate changes during a 75-g oral glucose challenge in 11 LQT2 patients and 22 matched 
control participants.  
Changes in QTcB (asterisks indicate significant change from baseline and are shown for groups separated because of interac-
tion between time and group) (A) and ∆ QTcB changes from baseline shown for both groups QTcB (asterisks indicate interaction 
between groups) (B). Changes in QTcF and heart rate (asterisks indicate significant change from baseline for groups analyzed 
together because there were no interactions between groups) (C and D) analyzed with a mixed-model ANOVA. LQT2 patients, 
red full lines; control participants, blue broken lines. Data are shown as means±SEM. *P<0.05. **P<0.01. ***P<0.001. 
****P<0.0001. LQT2 indicates long-QT syndrome type 2; and SEM, standard error of the mean.
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meal was missed and discomfort some hours after meal 
intake), some LQT2 patients may unwittingly regulate 
their eating habits to avoid serious hypoglycemia. Also, a 
known bias when monitoring glucose levels with a CGM is 
that study participants may adjust behavior toward less 
glucose intake and thereby reduce the risk of reactive 
hypoglycemia during the CGM test days.
Nonetheless, the glucose ingested, equivalent of 
a medium-size sugar-containing soft drink, did lead to 
reactive hypoglycemia in the majority of LQT2 patients 
with 18% experiencing serious hypoglycemia (<50 mg/
dL glucose). The hypoglycemia seemed to be coupled 
especially to mutations in the PAS domain. Severity anal-
ysis has identified the PAS domain of hERG as a region 
where mutations increase susceptibility to disease dra-
matically37 by causing severe trafficking defects.19 Seri-
ous incidences of hypoglycemia have previously been 
observed both in children with LQT233 and in LQT1.7 Our 
demonstration that LQT2 patients, also in the absence 
of β-blockers, have increased risk of reactive hypogly-
cemia should lead to a greater awareness of the risk 
of glucose-induced hypoglycemia in LQTS. The risk of 
reactive hypoglycemia can be lessened by reducing the 
intake of easily digestible carbohydrates. Thus, overall, 
among patients with congenital LQTS, hypoglycemia 
may prove to be more clinically relevant than currently 
appreciated; however, the association with QT-related ar-
rhythmias remains to be demonstrated.
Medications That Affect Kv11.1 Channels and 
Risk of Hypoglycemia
We here show that the selective Kv11.1 channel blocker 
dofetilide,27,28 which is used as an antiarrhythmic drug, in-
creases insulin secretion and lowers blood glucose after 
glucose intake in rats. Similarly, the widely used fluoroqui-
nolone antibiotics that also block the Kv11.1
1 have been 
associated with hypoglycemia both in patients with and 
without diabetes mellitus, and with fatal hypoglycemia, as 
well, when used together with sulfonylurea.1,38,39 Indeed, 
several widely used pharmaceutical agents are known 
to block the Kv11.1 channel,1,27 and may, therefore, on 
the background of the present observations, also be sus-
pected to increase the risk of reactive hypoglycemia.
GLP-1 and Hypoglycemia
In glucose-tolerant individuals, elevated postprandial 
GLP-1 responses are associated with reactive hypogly-
cemia, which can be pronounced40,41; for instance, after 
gastric bypass surgery.42 Furthermore, GLP-1–induced 
inhibition of glucagon secretion may aggravate hypogly-
cemia in such cases.40 Thus, the increased secretion of 
GLP-1 in LQT2 patients is likely to contribute to the in-
creased risk of hypoglycemia.
β-Blockers and Hypoglycemia
Ten of 11 LQT2 patients were on β-blocking agents, but 
were free of medication in the morning before examina-
tion. Thus, with 24 hours since the last dose and with a 
half-life of 3 hours, the concentration during the OGTT was 
minimal. In addition, previous human studies have shown 
that β-blocking agents have either no effect or a slightly in-
creasing effect on blood glucose,7,43,44 contrasting to the 
decreased glucose levels observed in the patients with 
LQT2, thus ruling out that the lower glucose levels among 
LQT2 in comparison with control participants could be at-
tributable to β-blocking agents. Actually, prior use may 
even have positive effects on recovery from hypoglyce-
mia,12 and a recent study of diabetic patients showed that 
prior use of β-blockers led to lower incidence of severe 
hypertension and hypokalemia during hypoglycemia and 
recommended incorporation of β-blockers for diabetes 
mellitus to reduce dangers associated with severe hypo-
glycemia.45
CONCLUSIONS
In conclusion, besides prolonged cardiac repolarization, 
LQT2 patients display exaggerated incretin and endo-
crine pancreatic function with increased GLP-1, GIP, and 
insulin secretion and defective glucagon levels, causing 
lower plasma glucose levels and thus an increased risk 
of hypoglycemia. Pharmacological Kv11.1 blockade 
(dofetilide) in rats had similar effects and inhibition of 
hERG in β and L cells directly increased insulin and GLP-
1 secretion by up to 50%. Because both postprandial 
hypo- and hyperglycemia influenced the QT interval in 
LQT2 patients, the risk of cardiac events may be further 
increased during glycemic excursions in LQT2. It may 
therefore be relevant to advice LQT2 patients to avoid 
Figure 6. Symptoms of hypoglycemia frequency 
and severity total score in 11 LQT2 patients and 22 
matched control participants.  
Data were analyzed with a paired t test and shown as 
mean±SEM. *P=0.04. See analysis of all questions in 
online-only Data Supplement Table III. LQT2 indicates long-QT 
syndrome type 2; and SEM, standard error of the mean.
 by guest on January 31, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
LQT2 (hERG) Associates With Reactive Hypoglycemia 
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2017;135:1705–1719. DOI: 10.1161/CIRCULATIONAHA.116.024279 May 2, 2017 1717
high sugar intake, which would limit both postprandial 
hyper- and hypoglycemia, to reduce this risk.
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Supplementary Methods 
Oral glucose tolerance test (OGTT) in rats 
 
Study approval was obtained from the Danish Animal Experiments Inspectorate (2013-15-
2934-00833). Female Wistar rats (~ 230 g) were purchased from Janvier Labs (Saint-
Berthevin Cedex, France ) and were allowed to acclimate for at least a week in a 12:12h 
light-dark cycle with ad libitum access to drinking water and standard chow. Rats were 
handled daily the week leading up to the experiment to minimize stress. On the day of 
experimentation, rats were fasted from 07:30 and the experiments were performed around 
17:00. Dofetilide (Tocris, Bioscience, Bristol, UK) was dissolved in PEG400/saline (1:1) on 
the day of experimentation. Rats were divided into weight-matched groups and received an 
I.V. injection under isoflurane anesthesia (4% in 100% O2) of dofetilide (5 mg/kg dofetilide) 
or vehicle 15 minutes prior to glucose gavage feeding. Half-life of dofetilide in female rats is 
1.2 hrs1. During gavage, all rats received a bolus of 2 g/kg glucose (500 mg/ml). The moment 
of glucose gavage was considered time 0 min. Blood was collected at time -15 (just prior to 
I.V. injection), 0 (just prior to glucose gavage), 15, 30 and 60 min. The blood samples were 
collected by sublingual vein puncture into pre-chilled EDTA-coated capillary tubes 
(Microvette 200 K3E, Sarstedt, Nümbrecht, Germany) and kept on ice. Blood glucose was 
measured immediately after collection with an Accu-chek Compact Plus meter (Roche, 
Mannheim, Germany). The samples were then centrifuged (1100 g, 15 min, 4 °C) and plasma 
was transferred to Eppendorf tubes and instantly frozen on dry ice. Plasma was stored at -20 
°C until analysis was performed. Plasma insulin levels were analyzed using rat insulin-
ELISA kit (Mercodia, Uppsala, Sweden). Data were analyzed by t-test.  
 
3 
Cells studies 
Cell culture 
GLUTag cells were grown in low glucose (1.0g/l) DMEM glucose supplemented with 10 % 
FBS and 1% (v/v) P/S and glutamax (Cat. No. 35050061, Gibco, Life Technologies 
Corporation, CA, USA). Min-6 cells were kindly provided by Professor Jens Højris Nielsen 
(University of Copenhagen, Denmark) and grown in DMEM (Cat. No. 31966-021, Gibco, 
Grand Island, USA) containing 5000U/ml Pen-Strep (Cat. No. 15140-122, Gibco) and 10 % 
fetal bovine serum (FBS) (Cat. No. Sv3016003, Thermo, Roskilde, Denmark). The cells were 
seeded in 24-well plates (NuncTM, Thermo Scientific) at a cell density of 4x104 per well.  
Quantitative polymerase chain reaction (qPCR) and small interfering RNAs 
Total RNA was extracted and isolated from cell lines and qPCR was performed with mouse 
HERG, primers (GeneCopoeia, Inc. Rockville, MD 20850 USA). The technique has 
previously been described2, 3.  Small interfering RNAs (siRNAs) against hERG were obtained 
as SMARTpool reagents from Santa Cruz Biotechnology, INC (Dallas, TX 75220 USA), and 
siRNA universal negative control was from Sigma-Aldrich (Brondby, Denmark). siRNA 
transfection was performed using OPTI-MEM® I and Lipofectamine™ 2000 (Invitrogen). 
The cultured cells were transiently transfected with the plasmids or with vector control using 
X-treme gene 6 Transfection Reagent (Cat. No. 063365787001, Roche Applied Science, 
Indianapolis, IN 46250, USA) according to the manufacturer’s instructions. Relative mRNA 
was calculated using the ΔΔCq method4.  
Stimulation protocol 
For acute stimulation protocols of cultured L- (GLUTag) and  β- (Min-6) cells (with/without 
siRNA hERG), we used ~80% confluent cells from different batch numbers (n=3). Cells were 
4 
incubated for 2 h with PBS (control) or 180 mg/dl (10 mmol/l)  glucose. After the end of the 
stimulation period, cell media were obtained and centrifuged (1,500 x g, 4°C, 5min) to 
remove any cells or debris and kept at -80°C until analysis.  
Biochemical measurements 
We diluted the cell media in assay buffer from each of the respective ELISAs to obtain levels 
within the dynamic range of the standard curves. Levels of insulin were measured using an 
ELISA from Mercodia (Cat. No. 10-1249-01, Uppsala, Sweden). Levels of GLP-1 were 
measured using a sandwich ELISA targeting total GLP-1 (amidated and glycine-extended 
forms) as previously described5. One-way ANOVA with a post hoc (Sidak Holm) correction 
for multiple testing was used to test for significance.   
 
Supplementary results 
Continuous glucose monitoring  
Six of the eleven LQT2 patients and six matched control subjects were examined with 
Continuous Glucose Monitoring (CGM) for the recommended minimum of three days6(4.3 ± 
1.0 days vs. 4.3 ± 1.0 days, p = 0.9). Unfortunately, none of the two patients who developed 
serious hypoglycemia (p-glucose <50mg/dl) during the OGTT, completed the CGM. Four out 
of 7 LQT2 patients (11 in total) and 2 out of the 8 controls (22 in total) with hypoglycemia 
(p-glucose <70 mg/dl) during OGTT also participated in the CGM.  
There were no differences in 24-hour blood glucose profiles. None of the examined 
participants were seriously hypoglycemic (p-glucose <50mg/dl) during the continuous 
examination period (supplementary table 1).  
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 Supplementary table 1. Continuous glucose monitoring 
Glucose 
(mg/dl) 
LQT2 patients Control participants p-value (LQT2 vs Control) 
>141 8 ± 4 min. 14 ± 11 min. 0.6 
70-141 1408 ± 9 min. 1371 ± 17 min. 0.1 
50-70 24 ± 11 min. 55 ± 19 min. 0.2 
<50 0 ± 0 min. 0 ± 0 min. 1.0 
Supplementary table 1. Continuous glucose monitoring (CGM) of 6 LQT2 patients and 6 
matched control participants presented as minutes per 24-hours in each glycemic interval. 
Difference between cases and control participants was analyzed with a mixed model 
ANOVA. The two patients who developed serious hypoglycemia during the OGTT, did not 
complete CGM. Data are shown as mean ± SD. 
 
Supplementary Table 2. Delta changes in ECG parameters 
Delta changes in ECG LQT2 patients 
Control 
participants 
p-value 
Maximum ∆ increase QTcB0-30 min. 
 
25.5 ± 3.6 14.4 ± 2.7 0.01 
Maximum ∆ increase QTcF0-30 min. 
 
19.1 ± 2.6 8.6 ± 1.9 0.004 
Maximum ∆ increase HR 0-30 min. 
 
5.2 ± 1.6 5.9 ± 1.3 0.6 
Supplementary Table 2. Delta changes in ECG parameters in 11 hERG patients and 22 
matched control participants during OGTT. Acute response to glucose ingestion (0-30 min) 
of QTcB, QTcF and heart rate (HR) analyzed with a mixed model ANOVA. Data are shown 
as mean ± SD. 
 
 
7 
Supplementary table 3. Hypoglycemia questionnaire. 
 Frequency (Point) Severity (Point) 
Symptom (N) LQT2 (11) Control (22) LQT2 (11) Control (22) 
1. Craving for 
sweets. 
1.5 ± 0.2* 2.3 ± 0.2* 1.4 ± 0.2 1.5 ± 0.1 
2. Irritability when 
a meal is missed out. 
1.8 ± 0.4 1.4 ± 0.3 1.4 ± 0.2 1.1 ± 0.2 
3. Feeling tired or 
weak when a meal is 
missed out. 
2.0 ± 0.3* 1.2 ± 0.2* 1.4 ± 0.2* 0.8 ± 0.1* 
4. Often hungry. 1.9 ± 0.3 2.2 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 
5. Dizziness when 
suddenly standing 
up. 
2.0 ± 0.3* 1.0 ± 0.2* 1.5 ± 0.2 0.9 ± 0.1 
6. Feeling dizzy in 
general. 
0.7 ± 0.2 0.3 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 
7. Feeling tired or 
uncomfortable some 
hours after a meal. 
1.3 ± 0.3* 0.6 ± 0.1* 1.1 ± 0.2 0.7 ± 0.1 
8. Trouble 
concentrating. 
1.5 ± 0.2 1.1 ± 0.2 0.8 ± 0.2 1.0 ± 0.1 
9. Heart 
palpitations. 
1.3 ± 0.3* 0.6 ± 0.1* 1.1 ± 0.2 0.8 ± 0.1 
10. Occasional 
shakiness. 
0.7 ± 0.2 0.6 ± 0.1 0.7 ± 0.2 0.7 ± 0.1 
11. Occasional 
blurry vision. 
0.8 ± 0.3 0.7 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 
12. Depression or 
mood swings. 
1.3 ± 0.3 0.8 ± 0.2 0.9 ±0.2 0.8 ±0.2 
13. Frequently 
anxious or nervous. 
0.6 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.6 ± 0.1 
14. Frequently 
aggressive. 
0.5 ± 0.2 0.8 ± 0.2 0.6 ± 0.2 0.8 ± 0.2 
15.  Frequently 
awakening at night. 
1.9 ± 0.3 1.9 ± 0.2 1.1 ± 0.2 1.4 ± 0.2 
16. Night sweats. 1.7 ± 0.3 1.5 ± 0.2 1.3 ±0.2 1.3 ± 1.2 
17. Frequently 
sweating. 
1.6 ± 0.2 1.6 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 
18. Occasionally 
fainting. 
0.6 ± 0.2* 0.1 ± 0.1* 0.9 ± 0.4 0.4 ± 0.1 
Supplementary table 3. Hypoglycemia questionnaire. *Significant (p<0.05) difference 
between cases and control participants performed with paired t-test. 73% (8/11) LQT2 
patients had a frequency score of 25 or higher vs 27% (6/22) controls; 6 of those 8 LQT2 
8 
patients vs 2 of those 6 controls had hypoglycemic plasma glucose levels during the OGTT 
(<70mg/dl). 82% (9/11) LQT2 patients vs 50% (11/22) controls had a frequency score of 19 
or higher; 7 (as in all LQT2 with hypoglycemia) of those 9 LQT2 patients vs 5 of those 11 
control participants had hypoglycemic glucose levels (<70mg/dl) during the OGTT. 7/11 
LQT2 vs 7/22 controls had a severity score of 20 or above; 6 of those 7 LQT2 and 2 of those 
7 controls had hypoglycemia during the OGTT. 
 
 
